Feedback (FDBK)

Sector:

Health Care

Index:

FTSE AIM All-Share

 20.50p
   
  • Change Today:
      0.000p
  • 52 Week High: 140.00p
  • 52 Week Low: 19.50p
  • Currency: UK Pounds
  • Shares Issued: 13.33m
  • Volume: 4,973
  • Market Cap: £2.73m
  • RiskGrade: 267
  • Beta: 0.43

Feedback inks collaboration deal with Vertex In Healthcare

By Josh White

Date: Wednesday 10 Jul 2024

LONDON (ShareCast) - (Sharecast News) - Clinical infrastructure specialist Feedback announced a collaboration agreement with Vertex In Healthcare, a clinical IT firm with a presence in the UK, the UAE, and South Africa, on Wednesday.
The AIM-traded firm said the strategic partnership aimed to combine key technologies and resell each other's products to drive commercial opportunities across multiple markets.

It said the agreement would see Feedback integrate the MedDream viewer into its Bleepa platform, which would allow Bleepa to be marketed directly to radiologists for primary diagnostic reporting, enhancing Feedback's teleradiology offering and expanding its market reach to new territories, particularly the US.

By embedding a viewer with regulatory approval in various international markets, the combined Bleepa-MedDream product would reportedly meet the necessary requirements for direct sales.

While Feedback's primary international focus remained on the growing market opportunity in India, the collaboration opened potential expansion into key markets such as the US and the Middle East.

The collaboration also positioned both Feedback and Vertex to resell each other's products in multiple regions, leveraging each other's established footprints to facilitate rapid and cost-effective market expansion.

Bleepa's value and product differentiation were expected to enhance Vertex's existing solutions, helping grow market share across various customer segments.

Additionally, Vertex would licence the database capabilities of Feedback's legacy Cadran PACS system, now integrated with the MedDream Viewer, to develop a PACS proposition for markets including South Africa and the UK.

"Vertex is a great partner for Feedback - like us it is commercially minded, ambitious and on a clear mission to improve healthcare," said chief executive officer Dr Tom Oakley.

"Our products naturally fit together and create a compelling value proposition to customers, especially those who are increasingly looking for the most streamlined and cost-effective way of procuring the solutions that they need.

"Incorporating the MedDream viewer into Bleepa opens up new opportunities for us, both domestically to radiologists and internationally, allowing us to expand more rapidly if we see opportunities overseas, avoiding some of the difficulties that we had in registering Bleepa as a medical device directly in India."

At 1005 BST, shares in Feedback were up 3.82% at 68p.

Reporting by Josh White for Sharecast.com.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

Feedback Market Data

Currency UK Pounds
Share Price 20.50p
Change Today 0.000p
% Change 0.00 %
52 Week High 140.00p
52 Week Low 19.50p
Volume 4,973
Shares Issued 13.33m
Market Cap £2.73m
Beta 0.43
RiskGrade 267

Feedback Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
22.85% above the market average22.85% above the market average22.85% above the market average22.85% above the market average22.85% above the market average
88.57% above the sector average88.57% above the sector average88.57% above the sector average88.57% above the sector average88.57% above the sector average
Price Trend
91.93% below the market average91.93% below the market average91.93% below the market average91.93% below the market average91.93% below the market average
89.19% below the sector average89.19% below the sector average89.19% below the sector average89.19% below the sector average89.19% below the sector average
Income Not Available
Growth
45.59% above the market average45.59% above the market average45.59% above the market average45.59% above the market average45.59% above the market average
77.78% above the sector average77.78% above the sector average77.78% above the sector average77.78% above the sector average77.78% above the sector average

What The Brokers Say

Strong Buy 0
Buy 1
Neutral 0
Sell 0
Strong Sell 0
Total 1
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

Feedback Dividends

No dividends found

Trades for 21-Nov-2024

Time Volume / Share Price
11:22 9 @ 20.00p
11:21 9 @ 20.90p
08:12 4,955 @ 20.00p

Feedback Key Personnel

CEO Tom Oakley
CFO Anesh Patel

Top of Page